Kamdar Gufran A, Chodvadiya Surbhi A, Paranjpe Radhika
Ophthalmology, Dr. D. Y. Patil Medical College, Hospital and Research Centre, Pune, IND.
Cureus. 2024 Nov 10;16(11):e73376. doi: 10.7759/cureus.73376. eCollection 2024 Nov.
Neovascular glaucoma (NVG) poses significant treatment challenges, often necessitating complex medication regimens to manage intraocular pressure (IOP). This report details a 65-year-old male with NVG secondary to central retinal artery occlusion (CRAO), who developed corneal epithelial bullae as a rare side effect of topical netarsudil therapy. Despite this complication, a continued treatment led to the gradual resolution of corneal lesions while maintaining controlled IOP. This case underscores the importance of vigilant monitoring for adverse effects and highlights the need for further research into netarsudil's safety profile in NVG management.
新生血管性青光眼(NVG)带来了重大的治疗挑战,通常需要复杂的药物治疗方案来控制眼压(IOP)。本报告详细介绍了一名65岁男性,患有继发于视网膜中央动脉阻塞(CRAO)的NVG,他出现了角膜上皮大疱,这是局部使用奈他地尔治疗罕见的副作用。尽管出现了这种并发症,但持续治疗导致角膜病变逐渐消退,同时眼压保持在可控范围内。该病例强调了警惕监测不良反应的重要性,并突出了对奈他地尔在NVG治疗中的安全性进行进一步研究的必要性。